Larimar Therapeutics (LRMR) Research & Development (2013 - 2026)
Larimar Therapeutics' (LRMR) quarterly Research & Development came in at $59.4 million in Q4 2025, up 122.05% YoY from $26.7 million in Q4 2024, and up 32.14% on a QoQ basis from $44.9 million in Q3 2025.
Larimar Therapeutics (LRMR) Research & Development (2013 - 2026) Analysis & Trends
Larimar Therapeutics (LRMR) has 13 years of Research & Development data on file, last reported at $59.4 million in Q4 2025.
- Quarterly Research & Development rose 122.05% year-over-year to $59.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $154.2 million (up 110.46% YoY) and the FY2025 annual result came in at $154.2 million, up 110.46% from the prior year.
- Research & Development advanced to $59.4 million in Q4 2025, from $44.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $59.4 million in Q4 2025 to a low of $4.6 million in Q1 2023.
- A 5-year average of $15.9 million and a median of $9.9 million in 2021 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development sank 60.21% — and 2024, when it soared 235.01%.
- Tracing LRMR's Research & Development over 5 years: stood at $6.3 million in 2021, then gained by 14.72% to $7.2 million in 2022, then jumped by 47.52% to $10.6 million in 2023, then jumped by 151.11% to $26.7 million in 2024, then soared by 122.05% to $59.4 million in 2025.
- The last three Research & Development figures came in at $59.4 million (Q4 2025), $44.9 million (Q3 2025), and $23.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Larimar Therapeutics | 452.93 Mn | 296.66 Mn | - | 28.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.00 Mn |
| Dec 31, 2025 | 59.37 Mn |
| Sep 30, 2025 | 44.93 Mn |
| Jun 30, 2025 | 23.37 Mn |
| Mar 31, 2025 | 26.55 Mn |
| Dec 31, 2024 | 26.74 Mn |
| Sep 30, 2024 | 13.92 Mn |
| Jun 30, 2024 | 19.68 Mn |
| Mar 31, 2024 | 12.94 Mn |
| Dec 31, 2023 | 10.65 Mn |
| Sep 30, 2023 | 6.59 Mn |
| Jun 30, 2023 | 5.88 Mn |
| Mar 31, 2023 | 4.56 Mn |
| Dec 31, 2022 | 7.22 Mn |
| Sep 30, 2022 | 5.58 Mn |
| Jun 30, 2022 | 5.64 Mn |
| Mar 31, 2022 | 5.81 Mn |
| Dec 31, 2021 | 6.29 Mn |
| Sep 30, 2021 | 14.03 Mn |
| Jun 30, 2021 | 9.10 Mn |